Drug Profile
Research programme: plasminogen-related peptides - Bio-Technology General/MGH
Alternative Names: Plasminogen-related peptide research programme - Bio-Technology General/MGH; PRP research programme - BTG/Massacheussetts General Hospital; Research programme: PRP - BTG/Massacheusetts General HospitalLatest Information Update: 28 Dec 2000
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer Massachusetts General Hospital; Savient Pharmaceuticals
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Dec 2000 Discontinued-Preclinical for Solid tumours in Israel (Unknown route)
- 28 Dec 2000 Discontinued-Preclinical for Solid tumours in USA (Unknown route)
- 30 Jul 1999 Preclinical development for Solid tumours in Israel (Unknown route)